SAN DIEGO, June 02, 2025 -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the...
Arthur Klausner to speak at Biotech & Life Science Global Venture Congress 2006 in New York City
News | 09. 14. 2006
